With the announcement by SIGA Technology (SIGA.O) to provide the anti-monkeypox treatment “Tpoxx”, questions return to the health complications that can result from its use, after the “tense” experience of Moroccans with coronavirus vaccines.
A company press release confirms that “Morocco’s access to this treatment as the first African country is part of a preventive context against any possible epidemic of this disease.”
The statement added that this drug is approved in the United States of America and Canada, has also obtained authorizations in Europe and the United Kingdom and has the capacity to “treating complications resulting from monkeypox vaccine.”
Health experts and pharmacists have reassured about the possible complications of this drug if it is officially used by the Ministry of Health and Social Protection.
Mohamed Aroua, health expert, explained that “ this drug represents progress and a continental distinction which makes Morocco capable of containing the disease if it spreads,” noting that “the issue of complications exists in all medications”.
Aroua added, in a statement to Hespress, that the drug “Tpoxx” is known on the African continent for its great effectiveness in the fight against monkeypox, noting that “the situation of this disease in Morocco is not completely worrying, but that does not prevent taking proactive measures such as acquiring treatments and providing a stock of vaccines.”
Regarding the reasons why Morocco chose treatment rather than the vaccine to strengthen this preventive measure, the same expert explained that “the presence of a single recorded case of monkeypox in Morocco makes the provision of treatment a priority, while the use of the vaccine requires the registration of thousands of cases » and emphasized that “drug complications are treated according to well-known rules within the international pharmaceutical market”emphasizing that “The most important thing is the proactive measure that Morocco has currently taken.”
For his part, Hamza Guedira, president of the National Council of the Order of Moroccan Pharmacists, estimated that “the absence of international reports on the presence of complications resulting from this drug, in addition to the surveillance imposed by the authorities on imported drugs, and the fact that the drug remains in the hands of the interests of the ministry and not on the market is a reassuring element for citizens. As for the effectiveness of the treatment, it remains only in the category of preventing the monkeypox epidemic.”
“Morocco’s position on the map of the spread of the disease on the African continent is very reassuring, and the Moroccan citizen should not be concerned or afraid of this disease,” noting that “the world has become aware and experienced during the Corona period, because conditions were “very difficult and confidence in vaccines subsequently weakened”he added.
In the current period, the same speaker confirmed that “the situation is controlled at the national and global level, and even within the hotspots of African countries, by taking the decision to provide vaccines, the Kingdom has played its necessary role in protecting citizens.”
